Thermal Neutron Capture Therapy of Malignant Melanoma:<i>in Vitro</i>Radiobiological Analysis

Nakanishi, Teruyuki; Ichihashi, M.; Mishima, Yutaka; Matsuzawa, Taiju; Fukuda, Hiroshi

doi:10.1080/09553008014550721

Cited by 22 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in broad agreement with the results of Fukuda et al (1987) and Kobayashi and Kandon (1982), who report an RBE of 6 for 10 B-capture products in melanoma cells, but rather higher than the value of 3.7 reported by Davies et al (1970). However, the effectiveness of the capture products depends to a large degree on the distribution of 10 B in the cell (Nakanishi et al, 1980). Studies with melanoma employ specific melanin precursors which concentrate in the cell thus increasing the effective 10 B concentration.…”

Section: Phantom Irradiationssupporting

confidence: 90%

The radiobiology of 24 keV neutrons

Morgan¹,

Mill²,

Roberts³

et al. 1988

The British Journal of Radiology

View full text Add to dashboard Cite

HeLa human carcinoma cells and V79 Chinese hamster fibroblasts have been irradiated in vitro with a beam of neutrons with a nearly pure 24 keV spectrum. The relative biological effectiveness (RBE) of the filtered neutron beam relative to 60Co gamma radiation was determined by irradiation of cell cultures "free-in-air". The values obtained for the RBE at 37% survival were 5.8 +/- 0.8, at a dose of 0.69 +/- 0.06 Gy for the HeLa cells and 3.14 +/- 1.1 at a dose of 1.09 +/- 0.091 Gy for the V79 cells. Cytogenetic analysis of the damage in irradiated V79 cells gave an RBE of 6.7 +/- 1.4. Irradiation in a polyethylene phantom markedly attenuated the beam's biological effect. For both cell lines 2 cm of polyethylene virtually eliminated cell killing. Addition of boron 10 to the medium led to increased cell killing and a value of 4 was obtained for the RBE of the 10B(n, alpha)7Li reaction in HeLa cells.

show abstract

Section: Phantom Irradiationssupporting

confidence: 90%

The radiobiology of 24 keV neutrons

Morgan¹,

Mill²,

Roberts³

et al. 1988

The British Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…The first boron-containing promazines were described by Nakagawa and Aono 162 in which the boron moieties were attached to the aliphatic nitrogen of CPZ. The results with these compounds were not very promising owing in part to their low aqueous solubility and the probability that this aliphatic nitrogen, in protonated form, was involved in the binding to melanin and, thereby, to melanoma cells, via a charge-transfer complex with an indole nucleus . The boron-containing quaternary ammonium compound may interfere with the compound's intracellular transit and in its binding to melanin.…”

Section: Other Compoundsmentioning

confidence: 99%

The Chemistry of Neutron Capture Therapy

et al. 1998

View full text Add to dashboard Cite

“…Research in the field of radiation biology and radiation oncology is particularly important. In 1987, on the basis of the results of the experimental, technical, and preclinical studies on BNCT of melanoma [ 11 , 12 , 13 , 14 , 15 , 16 , 17 ], Mishima et al applied BNCT with BPA for the first time in a patient with metastatic melanoma and obtained good local control of the tumor. Since then, until 2002, a total of 22 patients with melanoma were treated with BNCT [ 3 , 4 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ], which provided good tumor control and longer patient survival.…”

Section: Introductionmentioning

confidence: 99%

Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results

Fukuda

2021

Cells

View full text Add to dashboard Cite

BNCT is a radiotherapeutic method for cancer treatment that uses tumor-targeting 10B-compounds. BNCT for cutaneous melanoma using BPA, a phenylalanine derivative, was first initiated by Mishima et al. in 1987. This article reviews the radiobiological basis of melanoma control and damage to normal tissues as well as the results of clinical studies. Experimental studies showed that the compound biological effectiveness (CBE) values of the 10B (n, α)7Li reaction for melanoma control ranged from 2.5 to 3.3. The CBE values of the 10B (n, α)7Li reaction for skin damage ranged from 2.4 to 3.7 with moist desquamation as the endpoint. The required single radiation dose for controlling human melanoma was estimated to be 25 Gy-Eq or more by analyzing the 50% tumor control dose data of conventional fractionated radiotherapy. From the literature, the maximum permissible dose to human skin by single irradiation was estimated to be 18 Gy-Eq. With respect to the pharmacokinetics of BPA in patients with melanoma treated with 85–350 mg/kg BPA, the melanoma-to-blood ratio ranged from 2.1–3.8 and the skin-to-blood ratio was 1.31 ± 0.22. Good local tumor control and long-term survival of the patients were achieved in two clinical trials of BNCT conducted in Japan.

show abstract

Thermal Neutron Capture Therapy of Malignant Melanoma:in VitroRadiobiological Analysis

Cited by 22 publications

References 10 publications

The radiobiology of 24 keV neutrons

The radiobiology of 24 keV neutrons

The Chemistry of Neutron Capture Therapy

Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results

Contact Info

Product

Resources

About